Stock listing
Frankfurt:B9A BioArctic AB Aktie
German listing (Frankfurt) of BioArctic AB · home listing Stockholm:BIOAB
Follow BioArctic AB into a list and get an email when it puts out news.
Share price · FWB:B9A
€26.26 EUR -0.74 (-2.7%)
Close on Nov 20, 2026
- Day range
- €26.26 – €26.58 EURNov 20, 2026
- Market cap
- €2.33B EURAt the close on Nov 20, 2026 · price × 88.74M shares outstanding
- 52-week range
- €25.00 – €35.26 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €3,033 EURMedian day 0 shares · 39 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| OTC:BRCTF | $30.10 USD | +0.105 (+0.4%) | 673 | $29.39 | $30.10 | $29.39 | $30.00 | Close on Nov 19, 2026 |
| Frankfurt:B9A | €26.26 EUR | -0.74 (-2.7%) | — | €26.58 | €26.58 | €26.26 | €27.00 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:B9A · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €27.29 | -0.028 | -0.1% | €27.33 | €27.53 | €27.29 | 0 | |
| €27.32 | -0.507 | -1.8% | €27.61 | €27.81 | €27.30 | 126 | |
| €27.82 | +0.866 | +3.2% | €28.01 | €28.01 | €27.71 | 126 | |
| €26.96 | +0.734 | +2.8% | €26.96 | €26.96 | €26.96 | 200 | |
| €26.22 | -2.21 | -7.8% | €28.52 | €28.70 | €26.13 | 0 | |
| €28.43 | -0.143 | -0.5% | €28.53 | €28.62 | €28.38 | 2 | |
| €28.58 | +0.787 | +2.8% | €28.56 | €28.92 | €28.32 | 4 | |
| €27.79 | +0.466 | +1.7% | €27.79 | €27.79 | €27.79 | 1,852 | |
| €27.32 | +0.365 | +1.4% | €27.32 | €27.32 | €27.32 | 0 | |
| €26.96 | +0.478 | +1.8% | €26.91 | €27.02 | €26.90 | 734 | |
| €26.48 | -0.168 | -0.6% | €26.48 | €26.48 | €26.48 | 360 | |
| €26.65 | +0.137 | +0.5% | €26.65 | €26.65 | €26.65 | 0 | |
| €26.51 | +0.07 | +0.3% | €26.51 | €26.51 | €26.51 | 0 | |
| €26.44 | +0.988 | +3.9% | €25.56 | €26.57 | €25.53 | 0 | |
| €25.45 | -0.652 | -2.5% | €25.45 | €25.45 | €25.45 | 0 | |
| €26.11 | +0.77 | +3.0% | €26.11 | €26.11 | €26.11 | 0 | |
| €25.34 | -0.004 | 0.0% | €25.34 | €25.34 | €25.34 | 0 | |
| €25.34 | -0.675 | -2.6% | €25.34 | €25.34 | €25.34 | 0 | |
| €26.01 | +0.09 | +0.3% | €26.31 | €26.31 | €25.87 | 0 | |
| €25.92 | -0.061 | -0.2% | €25.92 | €25.92 | €25.92 | 0 | |
| €25.99 | +0.127 | +0.5% | €25.96 | €26.14 | €25.86 | 8 | |
| €25.86 | -0.242 | -0.9% | €25.87 | €25.87 | €25.86 | 492 | |
| €26.10 | -0.259 | -1.0% | €26.11 | €26.11 | €26.09 | 0 | |
| €26.36 | -0.20 | -0.8% | €26.36 | €26.36 | €26.36 | 0 | |
| €26.56 | -0.261 | -1.0% | €26.56 | €26.56 | €26.56 | 0 | |
| €26.82 | -0.038 | -0.1% | €26.88 | €26.88 | €26.80 | 430 | |
| €26.86 | +0.20 | +0.8% | €26.89 | €26.89 | €26.78 | 0 | |
| €26.66 | -0.248 | -0.9% | €26.66 | €26.66 | €26.66 | 0 | |
| €26.91 | -0.276 | -1.0% | €26.91 | €26.91 | €26.91 | 0 | |
| €27.18 | -0.412 | -1.5% | €27.23 | €27.23 | €26.88 | 0 | |
| €27.59 | -0.183 | -0.7% | €28.00 | €28.09 | €27.27 | 80 | |
| €27.78 | -1.315 | -4.5% | €27.78 | €27.78 | €27.78 | 0 | |
| €29.09 | +0.364 | +1.3% | €28.98 | €29.31 | €28.91 | 20 | |
| €28.73 | +0.665 | +2.4% | €28.14 | €28.75 | €28.12 | 0 | |
| €28.06 | -0.171 | -0.6% | €28.06 | €28.06 | €28.06 | 0 | |
| €28.23 | +0.527 | +1.9% | €28.23 | €28.23 | €28.23 | 220 | |
| €27.71 | -0.207 | -0.7% | €27.71 | €27.71 | €27.71 | 0 | |
| €27.91 | -0.435 | -1.5% | €27.91 | €27.91 | €27.91 | 0 | |
| €28.35 | +0.38 | +1.4% | €28.35 | €28.35 | €28.35 | 0 | |
| €27.97 | -0.846 | -2.9% | €27.97 | €27.97 | €27.97 | 0 | |
| €28.82 | -0.419 | -1.4% | €28.82 | €28.82 | €28.82 | 0 | |
| €29.23 | -0.185 | -0.6% | €29.23 | €29.23 | €29.23 | 0 | |
| €29.42 | +0.62 | +2.2% | €29.26 | €29.44 | €29.02 | 200 | |
| €28.80 | -0.625 | -2.1% | €28.80 | €28.80 | €28.80 | 0 | |
| €29.42 | -1.419 | -4.6% | €29.42 | €29.42 | €29.42 | 0 | |
| €30.84 | +2.212 | +7.7% | €30.84 | €30.84 | €30.84 | 68 | |
| €28.63 | +0.211 | +0.7% | €28.63 | €28.63 | €28.63 | 0 | |
| €28.42 | +0.022 | +0.1% | €28.42 | €28.42 | €28.42 | 0 | |
| €28.40 | -0.92 | -3.1% | €28.40 | €28.40 | €28.40 | 0 | |
| €29.32 | +0.046 | +0.2% | €29.32 | €29.32 | €29.32 | 0 | |
| €29.27 | +0.467 | +1.6% | €29.27 | €29.27 | €29.27 | 1,294 | |
| €28.81 | -2.494 | -8.0% | €28.81 | €28.81 | €28.81 | 0 | |
| €31.30 | +1.431 | +4.8% | €31.30 | €31.30 | €31.30 | 0 | |
| €29.87 | -0.629 | -2.1% | €29.87 | €29.87 | €29.87 | 0 | |
| €30.50 | +0.70 | +2.3% | €30.50 | €30.50 | €30.50 | 0 | |
| €29.80 | +0.153 | +0.5% | €29.80 | €29.80 | €29.80 | 8 | |
| €29.64 | +0.855 | +3.0% | €29.64 | €29.64 | €29.64 | 0 |
- Ticker
- Frankfurt:B9A
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Apr 21, 2026
BioArctic publishes the Annual Report and Sustainability Report for 2025
Latest earnings call · Aug 26, 2026
BioArctic (Stockholm:BIOA B) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Aug 26, 2026
Q2 2026 Earnings Presentation
Earnings · 23 slides
Latest news
BioArctic publishes the Annual Report and Sustainability Report for 2025
Apr 21, 2026
Closed €29.19 (-3.0%) on Apr 22, 2026
The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB
Mar 27, 2026
Closed €28.79 (-1.8%) on Mar 27, 2026
Latest data on long-term, real-world treatment with lecanemab will be presented at the AD/PD™ 2026 congress
Mar 11, 2026
Closed €29.26 (+4.4%) on Mar 11, 2026
Number of shares and votes in BioArctic AB (publ) as of February 27, 2026
Feb 27, 2026
Closed €28.23 (-4.3%) on Mar 2, 2026
Invitation to presentation of BioArctic's fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CET
Feb 11, 2026
Closed €30.20 (-2.4%) on Feb 11, 2026
BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China
Feb 9, 2026
Closed €28.98 (+1.9%) on Feb 9, 2026
Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025
Feb 6, 2026
Closed €28.45 (-0.8%) on Feb 6, 2026
Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA
Jan 25, 2026
Closed €29.34 (+0.7%) on Jan 26, 2026
BLA for subcutaneous formulation of Leqembi® accepted in China
Jan 6, 2026
Closed €28.97 (+0.1%) on Jan 6, 2026
Leqembi included in China's commercial insurance innovative drug list
Dec 8, 2025
Closed €29.25 (+4.4%) on Dec 9, 2025
BioArctic AB on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 10 in the last 12 months · 30 in all · newest Apr 21, 2026 · oldest 2025
- Calls
- 14 calls with a replay · 14 with a transcript · latest Aug 26, 2026
- Decks
- 27 decks · latest Aug 26, 2026
Where BioArctic AB is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Stockholm:BIOAB · Home listing | Stockholm | Sweden | SEK |
| gettex:B9A | gettex | Germany | EUR |
| LSIN:0RV2 | LSIN | United Kingdom | SEK |
| Aquis:BIOABS | Aquis | United Kingdom | SEK |
| OTC:BRCTF | OTC | United States | USD |
| LS Exchange:A2H5GS | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2H5GS | Lang & Schwarz | Germany | EUR |
| Tradegate:B9A | Tradegate | Germany | EUR |
| Frankfurt:B9A · This page | Frankfurt | Germany | EUR |
| Hamburg:B9A | Hamburg | Germany | EUR |
| Aquis:BIOABS | Aquis | United Kingdom | SEK |
| Dusseldorf:B9A | Dusseldorf | Germany | EUR |
| Munich:B9A | Munich | Germany | EUR |
| Stuttgart:B9A | Stuttgart | Germany | EUR |
| Turquoise:BIOABS | Turquoise | United Kingdom | SEK |
Valuation
P/E 212× against a median of 3.4×: the highest of 2 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- 20.45B SEK
- P/E
- 212×
- EV/sales
- 20.4×
- EV/EBITDA
- 90.0×
- Price/book
- 11.1×
- Gross margin
- 93.2%
- Operating margin
- 21.4%
- Net margin
- 10.5%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| BioArctic AB Class B · OMXSTO:BIOA_B | US$2.19B | US$2.00B | 212× | 20.4× | 90.0× | 11.1× | 10.5% | 0.0× | n/a |
| InSilico Medicine Cayman TopCo · HKEX:3696 | US$2.29B | US$1.71B | n/a | 30.3× | n/a | 4.2× | −626.5% | 0.0× | n/a |
| Arcus Biosciences, Inc. · NYSE:RCUS | US$2.25B | US$1.72B | n/a | 17.2× | n/a | 6.3× | −453.0% | 0.3× | 1.37 |
| SK bioscience Co.,Ltd. · KRX:302440 | US$2.24B | US$2.02B | n/a | 4.1× | n/a | 1.7× | −12.8% | 0.3× | n/a |
| NewAmsterdam Pharma Company N.V. · NASDAQ:NAMS | US$2.20B | US$1.57B | n/a | 60.6× | n/a | 3.5× | −789.9% | 0.0× | 1.41 |
| Lakefront Biotherapeutics · EURONEXT:LKFT | US$2.20B | −US$260.8M | 3.4× | −0.2× | n/a | 0.6× | 60.2% | 0.0× | n/a |
| Pharvaris N.V. · NASDAQ:PHVS | US$2.20B | US$1.89B | n/a | n/a | n/a | 7.5× | n/a | 0.0× | 0.76 |
| Beam Therapeutics Inc. · NASDAQ:BEAM | US$2.16B | US$1.22B | n/a | 8.3× | n/a | 2.3× | −73.9% | 0.1× | 1.90 |
| Celldex Therapeutics, Inc. · NASDAQ:CLDX | US$2.15B | US$1.50B | n/a | n/a | n/a | 3.3× | n/a | 0.0× | 1.07 |
| Palvella Therapeutics, Inc. · NASDAQ:PVLA | US$2.09B | US$1.85B | n/a | n/a | n/a | 10.6× | n/a | 0.0× | 1.50 |
| Regencell Bioscience Holdings Limited · NASDAQ:RGC | US$2.07B | US$2.06B | n/a | n/a | n/a | 155× | n/a | 0.0× | 1.57 |
| Median of the others | US$2.20B | US$1.71B | 3.4× | 12.8× | 3.8× | −263.4% | 0.0× | 1.41 |
Forecasts
Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 314.00 SEK · Analysts' mean
- EPS, year to Dec 2026
- 5.75 · 2 analysts
- Revenue, year to Dec 2026
- 1.52B · 3 analysts
Events
- Next results
- Nov 25, 2026 (expected)
Calls
| Call | When | Status |
|---|---|---|
| BioArctic (Stockholm:BIOA B) Q2 2026 Earnings Call | Wed, Aug 26, 2026 · 3:30 AM ET | Replay |
| BioArctic (Stockholm:BIOA B) Q1 2026 Earnings Call | Wed, May 20, 2026 · 1:00 AM ET | Replay |
| BioArctic (Stockholm:BIOA B) Q4 2025 Earnings Call | Wed, Feb 18, 2026 · 3:30 AM ET | Replay |
| BioArctic (Stockholm:BIOA B) Q3 2025 Earnings Call | Thu, Nov 13, 2025 · 3:30 AM ET | Replay |
| BioArctic (Stockholm:BIOA B) Q2 2025 Earnings Call | Thu, Aug 28, 2025 · 4:00 AM ET | Replay |
| BioArctic (Stockholm:BIOA B) Q1 2025 Earnings Call | Wed, May 21, 2025 · 3:30 AM ET | Replay |
| BioArctic (Stockholm:BIOA B) Q4 2024 Earnings Call | Thu, Feb 13, 2025 · 3:30 AM ET | Replay |
| BioArctic (Stockholm:BIOA B) Q3 2024 Earnings Call | Thu, Nov 14, 2024 · 3:30 AM ET | Replay |
| BioArctic (Stockholm:BIOA B) Q2 2024 Earnings Call | Thu, Aug 29, 2024 · 3:30 AM ET | Replay |
| BioArctic (Stockholm:BIOA B) Q1 2024 Earnings Call | Fri, May 17, 2024 · 3:30 AM ET | Replay |
All 14 calls
| Call | When | Status |
|---|---|---|
| BioArctic (Stockholm:BIOA B) Q4 2023 Earnings Call | Wed, Feb 14, 2024 · 3:30 AM ET | Replay |
| BioArctic (Stockholm:BIOA B) Q3 2023 Earnings Call | Wed, Nov 08, 2023 · 3:30 AM ET | Replay |
| BioArctic (Stockholm:BIOA B) Q2 2023 Earnings Call | Wed, Jul 12, 2023 · 3:30 AM ET | Replay |
| BioArctic (Stockholm:BIOA B) Q1 2023 Earnings Call | Thu, Apr 27, 2023 · 3:30 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q2 2026 | Aug 26, 2026 · Before open | −6.7% |
| Q1 2026 | May 20, 2026 · Before open | +1.5% |
| Q4 2025 | Feb 18, 2026 · Before open | +12.4% |
| Q3 2025 | Nov 13, 2025 · Before open | +7.2% |
| Q2 2025 | Aug 28, 2025 · Before open | +11.8% |
| Q1 2025 | May 21, 2025 · Before open | +11.0% |
| Q4 2024 | Feb 13, 2025 · Before open | +1.8% |
| Q3 2024 | Nov 14, 2024 · Before open | +29.9% |
| Q2 2024 | Aug 29, 2024 · Before open | +8.5% |
| Q1 2024 | May 17, 2024 · Before open | −0.8% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Feb 14, 2024 · Before open | +8.2% |
| Q3 2023 | Nov 8, 2023 · Before open | −1.8% |
| Q2 2023 | Jul 12, 2023 · Before open | +0.5% |
| Q1 2023 | Apr 27, 2023 · After close | +4.1% |
| Q4 2022 | Feb 3, 2023 · Before open | −1.8% |
| Q3 2022 | Oct 20, 2022 · Before open | +4.6% |
| Q2 2022 | Jul 12, 2022 · Before open | −3.1% |
| Q1 2022 | Apr 28, 2022 · Before open | −6.5% |
| Q4 2021 | Feb 3, 2022 · Before open | −1.3% |
| Q3 2021 | Oct 21, 2021 · Before open | −1.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q2 2026 Earnings Presentation | Earnings | 23 slides | Aug 26, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 26 slides | May 20, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 27 slides | Feb 18, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 27 slides | Nov 13, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 29 slides | Aug 28, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 23 slides | May 21, 2025 |
| Q4 2024 Earnings Presentation | Earnings | 19 slides | Feb 13, 2025 |
| Q3 2024 Earnings Presentation | Earnings | 23 slides | Nov 14, 2024 |
| Q2 2024 Earnings Presentation | Earnings | 22 slides | Aug 29, 2024 |
| Q1 2024 Earnings Presentation | Earnings | 22 slides | May 17, 2024 |
All 27 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q4 2023 Earnings Presentation | Earnings | 19 slides | Feb 14, 2024 |
| Q3 2023 Earnings Presentation | Earnings | 20 slides | Nov 8, 2023 |
| Q2 2023 Earnings Presentation | Earnings | 14 slides | Jul 12, 2023 |
| Q1 2023 Earnings Presentation | Earnings | 22 slides | Apr 27, 2023 |
| Q4 2022 Earnings Presentation | Earnings | 17 slides | Feb 3, 2023 |
| Clinical Trials on Alzheimer's Disease (CTAD) 2022 | Conference | 74 slides | Dec 2, 2022 |
| Technical Presentation (August 2022) | Technical | 9 slides | Aug 4, 2022 |
| Q2 2022 Earnings Presentation | Earnings | 17 slides | Jul 12, 2022 |
| Q1 2022 Earnings Presentation | Earnings | 18 slides | Apr 28, 2022 |
| FY2021 Earnings Presentation | Earnings | 21 slides | Feb 3, 2022 |
| Q2 2021 Earnings Presentation | Earnings | 16 slides | Jul 9, 2021 |
| Q1 2021 Earnings Presentation | Earnings | 16 slides | Apr 21, 2021 |
| FY2020 Earnings Presentation | Earnings | 16 slides | Feb 4, 2021 |
| Q3 2020 Earnings Presentation | Earnings | 18 slides | Oct 14, 2020 |
| Q2 2020 Earnings Presentation | Earnings | 18 slides | Jul 10, 2020 |
| Shareholder Meeting (2020) | Shareholder meeting | 6 slides | 2020 |
| Shareholder Meeting (May 2019) | Shareholder meeting | 10 slides | May 9, 2019 |
Financials
Annual, in SEK
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.00B | 257.4M | 616.0M | 228.3M | 23.1M | 62.3M | 281.8M | 714.0M | 140.7M | 105.6M |
| Cost of revenue | 59.2M | 27.0M | 15.0M | 74.3M | 55.1M | 50.2M | 72.4M | 145.4M | 266.0K | 238.0K |
| Gross profit | 1.94B | 230.4M | 601.0M | 154.0M | -31.9M | 12.1M | 209.4M | 568.6M | 140.4M | 105.4M |
| Research and development | 376.9M | 311.1M | 172.1M | 74.3M | 55.1M | 50.2M | 72.4M | 145.4M | 101.6M | 53.7M |
| Selling, general and administrative | 115.7M | 93.4M | 128.5M | 115.7M | 24.9M | 23.4M | 31.2M | 31.9M | 31.5M | 14.5M |
| Operating income | 1.26B | -228.5M | 252.6M | -10.2M | -139.7M | -82.3M | 112.5M | 488.8M | 19.3M | 74.6M |
| Depreciation and amortization | 12.8M | 10.7M | 18.4M | 14.6M | 13.1M | 10.9M | 9.20M | 2.06M | 1.99M | 1.56M |
| EBITDA | 1.27B | -217.8M | 271.1M | 4.47M | -126.6M | -71.4M | 121.7M | 490.9M | 21.3M | 76.2M |
| Interest expense | 37.9M | 1.85M | 10.4M | 2.12M | 984.0K | 1.10M | 1.19M | 1.37M | 647.0K | 5.00K |
| Income before tax | 1.26B | -189.5M | 276.5M | -11.2M | -140.5M | -86.7M | 113.0M | 489.6M | 19.7M | 74.1M |
| Income tax | 233.3M | -12.4M | 47.2M | 11.0K | -20.7M | -18.2M | 24.5M | 108.0M | 4.53M | 16.6M |
| Net income | 1.02B | -177.1M | 229.2M | -11.2M | -119.8M | -68.5M | 88.5M | 381.6M | 15.2M | 57.6M |
| Earnings per share, basic | 1,155,000.00 | -200,000.00 | 260,000.00 | -0.13 | -1.36 | -0.78 | 1.00 | 4.33 | 0.17 | 0.65 |
| Earnings per share, diluted | 1,152,000.00 | -200,000.00 | 259,000.00 | -13.00 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1.04B | 512.9M | 611.6M | 805.4M | 848.4M | 999.9M | 1.11B | 917.3M | 1.11B | 692.5M |
| Short-term investments | 1.15B | 266.0M | 500.0M | |||||||
| Receivables | 121.6M | 71.2M | 223.0K | 0 | 2.84M | 5.60M | 28.7M | 462.3M | 17.3M | 634.0K |
| Inventory | -223.0K | 7.50M | 1 | 2.94M | -462.3M | 2.81M | -634.0K | |||
| Current assets | 2.49B | 1.01B | 1.15B | 820.8M | 861.8M | 1.01B | 1.14B | 1.38B | 1.13B | 699.5M |
| Property, plant and equipment | 36.9M | 39.5M | 23.5M | 23.5M | 17.0M | 39.9M | 37.1M | 9.29M | 7.09M | 5.64M |
| Total assets | 2.58B | 1.11B | 1.19B | 858.3M | 897.7M | 1.05B | 1.18B | 1.39B | 1.14B | 708.0M |
| Accounts payable | 23.9M | 50.5M | 29.9M | 21.5M | 11.8M | 14.3M | 8.22M | 14.8M | 7.59M | 11.7M |
| Current liabilities | 520.8M | 175.7M | 125.0M | 70.9M | 101.3M | 108.7M | 149.2M | 342.8M | 498.9M | 643.1M |
| Total debt | 44.1M | 54.2M | 4.98M | 10.0M | 15.9M | 20.8M | 27.4M | |||
| Total liabilities | 608.1M | 216.7M | 139.5M | 72.1M | 109.1M | 143.0M | 208.8M | 375.3M | 504.3M | 647.2M |
| Shareholders' equity | 1.97B | 894.9M | 1.05B | 786.2M | 788.7M | 907.3M | 974.5M | 1.02B | 636.1M | 60.8M |
| Shares outstanding | 88.7M | 88.5M | 88.5M | 88.1M | 88.1M | 88.1M | 88.1M | 88.1M | 88.1M | 88.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1.43B | -316.3M | 309.7M | -31.6M | -140.5M | -92.3M | 327.2M | -200.1M | -135.3M | 675.1M |
| Capital spending | -10.2M | -26.6M | -7.44M | -12.7M | -4.39M | -12.5M | -3.26M | -4.25M | -3.45M | -2.97M |
| Free cash flow | 1.42B | -343.0M | 302.3M | -44.4M | -144.8M | -104.8M | 323.9M | -204.3M | -138.8M | 672.2M |
| Cash from investing | -894.6M | 205.6M | -507.5M | -12.8M | -4.41M | -12.5M | -3.27M | -3.08M | -2.81M | -2.97M |
| Cash from financing | 26.9M | 5.69M | 14.1M | -2.81M | -7.39M | -6.60M | -138.5M | -138.5M | 560.2M | -105.1M |
| Dividends paid | -26.0M | -6.02M | -15.0M | -5.99M | 0 | 0 | -132.1M | -132.1M | -132.1M | -105.1M |
| Share buybacks | 6.02M | 15.0M | 5.99M | 0 | 560.2M | |||||
| Change in cash | 563.3M | -105.0B | -183.7B | -47.2B | -152.3M | -112.8M | 195.5M | -193.1M | 417.8M | 578.7M |
Cap table
Built by 6ix from BioArctic AB Class B’s releases
- Common shares
- 74,344,689
- Fully diluted
- 74,344,689
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 74,344,689 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 74,344,689 |
Log in to ask 6ix AI your own questions about BioArctic AB.